• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Intersect ENT files with FDA for drug-delivering sinus implant

August 1, 2016 By Fink Densford

Intersect ENTIntersect ENT (NSDQ:XENT) said today it submitted a supplemental premarket approval submission to the FDA seeking approval for a new Nova steroid releasing implant for treating patients with chronic sinus disease.

The new Nova device is designed with a lower profile to allow for placement in smaller sinus openings, and will expand the usable patient population for the steroid releasing implants, the Menlo Park, Calif.-based company said.

“This submission is another important milestone in our efforts to address unmet needs for chronic sinusitis patients across the continuum of care. Nova design, which allows for placement in smaller sinus openings, has the potential to be an important option for physicians treating and managing chronic sinus disease,” CEO Lisa Earnhardt said in a press release.

A cohort from the company’s Progress study examined the use of the Nova device in 80 patients, which met its primary efficacy endpoint and reported a 65% relative reduction in the need for additional surgical procedures or oral steroid prescriptions. Device placement rate was 100% during the trial, with no device-related adverse events through a 90-day follow up.

In March, Intersect ENT said it won FDA premarket approval for an expanded indication for its Propel mini steroid releasing sinus implant designed to treat patients undergoing frontal sinus surgery.

The expanded indication from the company will allow the company to market the placement of the Propel mini in the frontal sinuses behind the eyebrows. Previous indication only allowed for placement in the ethmoid sinuses behind the bridge of the nose.

Filed Under: Drug-Device Combinations, Food & Drug Administration (FDA), Otolaryngology Ear, Nose & Throat, Regulatory/Compliance Tagged With: Intersect ENT Inc.

IN CASE YOU MISSED IT

  • Senseonics stock is up on Q2 results
  • MedAlliance wins second FDA IDE nod for drug-coated balloon
  • Wells Fargo downgrades Tandem amid rise of automated insulin delivery competition
  • FDA approves first targeted infusion therapy for HER2-low breast cancer
  • Abbott, WeightWatchers partner on diabetes care

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS